

8:45 am	Registration/Coffee, Pastries and Fruit
9:30	Welcome
0.45	KDA President
9:45	KDA Keynote Address
10:00	Ms. Susanne Waite, Founder and President Emeritus The Ten Things I've Learned in My 25 Years with KD
10.00	Ed Meyertholen, PhD
10:30	The KD Family: Genetics, Testing, and the Implications
10.30	Alice Schindler, Lead Genetics Counselor, NIH/NINDS
10:55	Break
11:15	What We Are Learning About Carriers
	Abdullah AlQahtani, MD, MPH
	Johns Hopkins University
11:40	What's New in Mobility Devices?
	Jim Kissling, President, AutoFarm Mobility
	Note: Mobility devices will be on display in Salon 4.
12:00 pm	Lunch
1:30	How to Increase the Impact of the KDA
	Terry Thompson, KDA President
	Lew Myers, KDA Fundraising Advisor
1:45	KDA Umbrella Organizations: Value to KD Patients
	Brian Lin, MDA,
	Alli Ward, NORD
2:10	An Emotional Roadmap for the Journey with Kennedy's Disease
	Dr. John Weaver, Psy.D.
2.00	Owner, Stress Management & Mental Health Clinics
3:00	Break
3:30	Breakout Sessions (in-person only)
	KD Men – Moderator: Jameson Parker
	KD Carriers – Moderator: Heather Montie
	KD Spouses/Caregivers - Moderator: JoDee Coulter
5:00	Conference Sessions End for the Day
6:00	Reception and Beginning of Silent Auction
7:00	Dinner (included with registration)
	Ballroom D

7:30 am	Breakfast Buffet
8:20	Welcome to Day 2 and Announcements
	KDA President
8:30	Tips and Tricks for KD Men, with Q&A
	Moderator: Jameson Parker, KDA Vice President
	KDA Board Members
9:00	Tips from an Occupational Therapist
	Kathleen Farrell, OTR/L, Occupational Therapist, NIH
9:25	NIH Natural History Study: Results and Implications Chris Grunseich, MD, NIH/NINDS
9:50	Break
10:20	Advice from a KD Clinician, with Q&A
	Tahseen Mozaffar, MD, University of California, Irvine
	With NIH clinicians Angela Kokkinis, Chris Grunseich, Abdullah
	AlQahtani
11:00	A Primer on KD Research
	Ed Meyertholen, PhD
11:30 pm	Lunch
1:00	Keynote Address for Research
	Kurt Fischbeck, MD, NIH (emeritus)
1.00	Al La Spada, MD, PhD, University of California, Irvine
1:20	Unexpected Prevalence of KD Gene Mutation
1.10	Matteo Zanovello, University College, London
1:40	Clinical Trials Update
	Overview: Chris Grunseich, MD, NIH/NINDS Vissia Viglietta, MD, PhD, Nido Biosciences – <i>Nido-361 Update</i>
	Gianni Soraru, MD, University of Padua – Update on Clenbuterol
	trial
	Milan Barnes, PT, Kruthika Doreswamy, MPH, and Michaele
	Sheehan, PT, NIH – Use of wearable sensors in SBMA
2:30	Break
3:00	Reports from KDA Grant Recipients
	 Carlo Rinaldi, MA, MD, PhD, Oxford University – Harnessing
	polyQ AR transcriptional activity to advance a gene therapy
	strategy in the SBMA clinic
	 Shinichiro Yamada, MD, PhD, Nagoya University –
	Pathophysiology and development of symptomatic therapy for

	 cold paresis in SBMA Alyson Sujkowski, PhD, Wayne State University – Using Drosophila exercise for therapeutic discovery in Kennedy's Disease Kerri Schellenberg, MD, MMedEd, University of Saskatchewan – Clinical characteristics and prevalence of KD in the indigenous populations of western Canada Silvia Fenu, MD, Carlo Besta Institute, Milan – Connecting SBMA international registries/databases: a retrospective study
4:00	Research Summary and Q&A , with senior researchers and lab
	heads
	Moderator: Diane Merry, PhD, Thomas Jefferson University
5:00	Conference Ends for the Day

7:30 am	Breakfast Buffet
	Foyer
8:20	Conference Updates and Introduction of Research Panels
	KDA President
	Panel Coordinator: Andy Lieberman, MD, PhD, University of Michigan
8:30	Panel 1: Disease Mechanisms
	Moderator: Andy Lieberman, MD, PhD, University of Michigan
	 Janghoo Lim, PhD, Yale University – Protein Homeostasis in the Pathogenesis of
	SBMA
	 David Luong, La Spada Lab, UC Irvine – Delineating novel pathways of motor
	neuron demise in SBMA
	 Diane Merry, PhD, Thomas Jefferson University, <i>Tissue-specific repeat instability in</i> SBMA
	 Caroline Rodrigues, PhD, Miranda Lab, Case Western Reserve University – Stem cell modeling of SBMA
	• Heather Montie, PhD, Philadelphia College of Osteopathic Medicine – <i>Does CD38 disrupt skeletal muscle function in KD</i> ?
	 Laura Bott, PhD, Northwestern University – Interindividual variation in protein
	misfolding disease: Lessons from the model organism C. elegans
10:00	Break
10:30	Panel 2: Translational Targets
	Moderator: Diane Merry, PhD, Thomas Jefferson University
	• Gianni Soraru, MD, University of Padua - Hearing function in KD: a case control study from a tertiary referral center
	 Caterina Marchioretti, PhD, University of Padua – From molecular pathogenesis to
	pharmacological intervention targeting skeletal muscle
	 Riccardo Cristofani, PhD, University of Milan – Proteostasis of androgen receptor
	 Ramesh Narayanan, PhD, University of Tennessee – Update on the preclinical
	development of AR N-Terminus domain binding degrader ONCT-505 for the
	treatment of KD
	• Agamjot Sangotra and Andy Lieberman, University of Michigan – Harnessing
	protein quality control to degrade polyglutamine AR in SBMA
	• Ambra Speciale, DPhil candidate, Oxford University – RNA editing dysregulation in
	SBMA: molecular mechanisms and therapeutic implications
	Brad Turner, PhD, and Jibao Yuan, University of Melbourne, Florey Institute –
	Developing a brain-penetrating antisense treatment approach for SBMA
12:15 pm	Conference Wrap-up
	KDA President
12:30	Conference Ends for All but Researchers
1:00	Researcher Luncheon and Discussion
3:00	End of <i>KDA 2024</i> Conference